<DOC>
	<DOCNO>NCT03004261</DOCNO>
	<brief_summary>Human cytomegalovirus ( CMV ) infection major cause morbidity mortality recipient allogeneic hematopoietic stem cell transplantation ( HSCT ) . propose study immunologic virologic effect donor derive CMV specific cytotoxic T lymphocyte ( CMV-CTL ) give transplant recipient CMV antigen peptide use induce CMV antigen specific T lymphocytes derive donor peripheral blood mononuclear cell period 18~21 days.The patient receive CMV-CTL cell sero-positive CMV-DNA 30 day transplant . The CMV-DNA level monitor weekly transfusion .</brief_summary>
	<brief_title>CMV-CTL Treatment CMV Infection After HSCT</brief_title>
	<detailed_description>Allogeneic hematopoietic stem cell transplantation widely use treatment hematological malignancy bone marrow failure disease . Human cytomegalovirus ( CMV ) infection major cause morbidity mortality recipient allogeneic hematopoietic stem cell transplantation ( HSCT ) . Approximately half recipient would develop CMV infection transplant . Present treatment recommendation CMV infection include ganciclovir foscarnet . However , medication many side effect , serious myelosuppression renal injury , moreover , many patient response medication . Considering risk associate persistent infection potential CMV specific cytotoxic T lymphocyte ( CMV-CTL ) restore immunity , propose study immunologic virologic effect donor derive CMV-CTL give transplant recipient , level CMV-CTL CMV DNA measure CTL recipient . If patient donor eligible , take 80 ml fresh blood donor 5 ml peripheral blood stem cell donor.The peripheral blood mononuclear cell separate peripheral blood peripheral blood stem cell . CMV antigen peptide use induce CMV-CTL period 18~21 day . The donor derive CMV-CTL cell transfuse patient ' intravenous line . The patient receive dose CMV-CTL cell sero-positive CMV-DNA 30 day transplant . The CMV-DNA level monitor weekly least 60 day transplant . If initial dose CMV-CTL cell patient develop viral infection , may eligible receive one additional injection CTLs . If CMV level blood continue rise dose T cell patient receive treatment Ganciclovir , Foscarnet .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Foscarnet</mesh_term>
	<mesh_term>Phosphonoacetic Acid</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Any allogeneic stem cell transplant recipient ≥ 14 year age ≤ 60 year age Bilirubin/ SGOT/SGPT &lt; 5 × upper normal limit . Creatinine &lt; 2 × upper normal limit . Ejection fraction ≥ 50 % , severe arrhythmia . Estimated life expectancy ≥ 6 month . Patients ' CMVDNA ≥ 1000cp/ml treatment group negative prophylactic group . Patients receive prednisone ≥ 1mg/kg/d treatment acute GVHD mild , severe chronic GVHD . Recipient &lt; 14years age Donor seropositive HBV/HCV/HIV RPR .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>cytomegalovirus infection</keyword>
	<keyword>cytotoxic T lymphocyte</keyword>
	<keyword>hematopoietic stem cell transplantation</keyword>
</DOC>